Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
- CLEVELAND, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2024:
- 09/03/2024
|
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CLEVELAND, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 09/02/2024
|
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
- CLEVELAND, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members to its Board of Directors. Dr. Zeiher brings more than 20 years of drug development experience where, in various roles, he oversaw the approval of 15 new treatments that addressed unmet needs in serious diseases with few to no treatment options. Dr. Crombez currently serves as Chief Medical Officer of Ultragenyx Pharmaceutical Inc. and brings extensive expertise in the development and execution of clinical development programs for rare genetic disorders.
- 08/14/2024
|
Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
- CMS grants ICD-10-PCS product-specific procedure code and favorable DRG assignment for pz-cel, supporting efficient hospital billing, reimbursement and patient access CMS grants ICD-10-PCS product-specific procedure code and favorable DRG assignment for pz-cel, supporting efficient hospital billing, reimbursement and patient access
- 08/13/2024
|
Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
- Significant progress addressing CMC items noted in CRL BLA resubmission remains on track for 2H 2024 CLEVELAND, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2024 and recent corporate progress. “Having completed data generation for nearly all of the Chemistry Manufacturing and Controls deliverables outlined in the Complete Response Letter that we received in April 2024, we are on track to resubmit our Biologics License Application for pz-cel this year and, if approved, bring a treatment option to patients with recessive dystrophic epidermolysis bullosa,” said Vish Seshadri, Chief Executive Officer of Abeona.
- 08/12/2024
|
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 08/01/2024
|
Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones
- Abeona Therapeutics Inc.'s BLA resubmission of Pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa is expected 2nd half of 2024. If Pz-cel is approved by the FDA, the company believes that it could reach peak U.S. sales of >$500 million by year 5 of the gene therapy being sold. FDA approval of Pz-cel for RDEB would allow Abeona to obtain a Priority Review Voucher, which it could keep or sell to another company for a considerable amount of cash.
- 07/12/2024
|
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
- CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced an agreement by which Beacon will evaluate Abeona's patented AAV204 capsid for the development and commercialization of potential gene therapies for select ophthalmology indications.
- 07/11/2024
|
Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
- CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona's Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Stifel Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 9:45 a.m. Eastern Time.
- 07/08/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ:ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/09/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/07/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/05/2024
|
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CLEVELAND, June 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 06/03/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ:ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/01/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/30/2024
|
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
- CLEVELAND, May 28, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its senior management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. Eastern Time. The Company will also participate in one-on-one investor meetings at the conference.
- 05/28/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- NEW YORK , May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/23/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/16/2024
|
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
- BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2024 and recent corporate progress. “We are grateful to our existing as well as new investors who have demonstrated their support through the recent financing, which has extended our cash runway into 2026, well beyond anticipated regulatory milestones,” said Vish Seshadri, Chief Executive Officer of Abeona.
- 05/15/2024
|
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CLEVELAND, May 07, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 05/07/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
- NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 05/06/2024
|
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,142,656 shares of its common stock, at an offering price of $4.07 per share, which is equal to the closing price on Thursday, May 2, 2024, or $4.0699 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the pre-funded warrants are exercised in full. The closing of the offering is expected to occur on or about May 7, 2024, subject to the satisfaction of customary closing conditions.
- 05/03/2024
|
Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL
- Abeona Therapeutics is a gene therapy company with a lead product candidate, Pz-cel, for recessive epidermolysis bullosa, or RDEB. Pz-cel has shown higher efficacy than the competition in treating larger skin lesions in RDEB. Despite receiving a complete response letter from the FDA, Abeona believes the manufacturing issues can be resolved and plans to submit a response by Q3 this year.
- 05/02/2024
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) investors concerning the Company's possible violations of federal securities laws. On April 22, 2024, Abeona disclosed that it had received a Complete Response Letter (“CRL”) from the FDA regarding its recessive dystrophic epidermolysis bullosa treatment, pz-cel, stating that “the FDA noted that certain additional information.
- 05/01/2024
|
The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On April 22, 2024, Abeona disclosed that it had received a Complete Response Letter (“CRL”) from the FDA regarding its recessive dystrophic epidermolysis bullosa treatme.
- 04/29/2024
|
Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost
- Abeona Therapeutics Inc. stock dropped by over half after receiving a Complete Response Letter from the FDA regarding its Biologics License Application for pz-cel. The FDA identified manufacturing issues that need to be resolved, delaying the potential approval of pz-cel. However, no issues were raised regarding efficacy and safety, nor are more trials required. Despite the setback, Abeona Therapeutics may present a buying opportunity as it bottoms out, with estimated peak revenue of over $500 million in the U.S. assuming approval.
- 04/23/2024
|
Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today?
- Abeona Therapeutics (NASDAQ: ABEO ) stock is falling on Tuesday after getting a Complete Response Letter ( CRL ) from the Food and Drug Administration (FDA). The CRL from the FDA notes that the regulator needs additional Chemistry Manufacturing and Controls ( CMC ) information from Abeona Therapeutics.
- 04/23/2024
|
US FDA declines to approve Abeona's skin disorder treatment
- Abeona Therapeutics said on Monday the U.S. health regulator had declined to approve its treatment for a rare skin blistering condition.
- 04/22/2024
|
Abeona Therapeutics Provides Regulatory Update on Pz-cel
- Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new clinical studies requested by FDA to support approval Anticipates completing and submitting requested CMC information in 3Q 2024 Conference call and webcast on Tuesday, April 23, 2024 at 8:30 a.m. ET to provide details on the requested CMC information CLEVELAND, April 22, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced a regulatory update for prademagene zamikeracel (pz-cel).
- 04/22/2024
|
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CLEVELAND, April 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 04/01/2024
|
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
- - FDA completed Pre-License Inspection of Abeona's Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study - - FDA completed Pre-License Inspection of Abeona's Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study -
- 03/18/2024
|
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CLEVELAND, March 05, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 03/05/2024
|
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 02/01/2024
|
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
- - On track for PDUFA target action date of May 25, 2024 - CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced, as part of the review process by the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB), completion by the FDA of both a Bioresearch Monitoring (BIMO) inspection of Abeona and the BLA mid-cycle review meeting. The BIMO inspection was conducted from January 22, 2024 through January 24, 2024 at Abeona's headquarters in Cleveland, Ohio, and reviewed the conduct and practices that pertain to the clinical studies of pz-cel.
- 02/01/2024
|
Abeona Therapeutics Announces $50 Million Credit Facility
- CLEVELAND, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has entered into a $50 million credit facility with the Avenue Venture Opportunities Fund, L.P. The credit agreement, which has a term of three and a half years, includes a first tranche of $20 million at closing, a second tranche of $10 million of committed capital, and an additional accordion option to upsize the credit facility by an additional $20 million upon satisfaction of certain terms and conditions.
- 01/08/2024
|
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CLEVELAND, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- 12/15/2023
|
Abeona Therapeutics stock climbs after drug candidate receives FDA Priority Review
- Abeona Therapeutics Inc shares jumped 15% to $4.96 in late-morning trading on Monday after the US Food and Drug Administration (FDA) said it would expedite a review of pz-cel (prademagene zamikeracel), the company's proposed treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare, inherited connective-tissue disorder. The clinical-stage biopharmaceutical company had previously stated that it expected an FDA decision on priority-review status by late November.
- 11/27/2023
|
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
- - PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel), Abeona's investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of May 25, 2024.
- 11/27/2023
|
The 7 Most Undervalued Penny Stocks to Buy in October 2023
- Investing in undervalued penny stocks is always going to be about the same few things. Most investors are attempting to find cheap, short-term plays with reasonable catalysts in their favor.
- 10/06/2023
|
3 Biotech Blockbusters to Turn $5,000 Into $50,000
- Investing in biotech stock can provide investors with immense rewards but also substantial risks. The key is finding the right balance.
- 09/12/2023
|
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
- CLEVELAND, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2023:
- 09/07/2023
|
Abeona Therapeutics Inc. (ABEO) Q2 2023 Earnings Call Transcript
- Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Greg Gin - Vice President of Investor Relations and Corporate Communications Vish Seshadri - Chief Executive Officer Joe Vazzano - Chief Financial Officer Madhav Vasanthavada - Vice President, Business Development Brian Kevany - Chief Technical Officer Conference Call Participants Maury Raycroft - Jefferies Kristen Kluska - Cantor Fitzgerald David Bautz - Zacks Small Capital Research Operator Good day, and welcome to the Abeona Therapeutics Second Quarter 2023 Update Conference Call [Operator Instructions]. As a reminder, today's conference is being recorded.
- 08/12/2023
|
3 Penny Stocks To Watch Before Next Week; Time To Buy?
- Penny stocks often represent an intriguing opportunity for investors. Defined by the U.S. Securities and Exchange Commission as shares trading for less than $5, these stocks generally belong to small companies that may not yet have made their mark in the mainstream market.
- 06/05/2023
|
Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
- CLEVELAND, May 22, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has changed the date of its previously announced First Quarter 2023 Portfolio Update conference call and webcast to Wednesday, May 24, 2023, at 8:30 a.m. ET. The call was previously scheduled for Tuesday, May 23, 2023, at 8:30 a.m. ET.
- 05/22/2023
|
Three Small-Cap Biotech Stocks to Consider Now
- This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023
- 12/12/2022
|
PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week
- We're checking in on the top short squeeze stocks to watch this week as traders continue to have an interest in this part of the market! Short squeeze stocks are often subject to volatility with massive gains.
- 11/21/2022
|
5 Penny Stocks To Buy According To Analysts, Targets Up To 995%
- Analysts say these are penny stocks to buy. Do you agree?
- 11/08/2022
|
Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value
- Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Should EB-101 be approved by FDA for RDEB, it would give company a Priority Review Voucher, which could be sold for around $100 million or more to another pharmaceutical company.
- 10/19/2022
|
Best Penny Stocks To Buy? 3 To Watch During The Stock Market Crash
- Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?
- 10/10/2022
|
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
- Best penny stocks to buy? Biotech penny stocks are heating up & these 4 might be worth watching now.
- 10/07/2022
|
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
- NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 3:30 p.m. EDT.
- 06/06/2022
|
Abeona Therapeutics (ABEO) CEO, Vishwas Seshadri on Q1 2022 Results - Earnings Call Transcript
- Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Vishwas Seshadri - Chief Executive Officer Joseph Vazzano - Chief Financial Officer Brian Kevany - Chief Technical Officer, Head of Research Greg Gin - Vice President, Investor Relations and Corporate Communications Conference Call Participants Maury Raycroft - Jefferies Rick - Cantor Fitzgerald Operator Good morning ladies and gentlemen, thank you for standing by. Welcome to the Abeona Q1 2022 earnings call.
- 05/17/2022
|
Abeona Therapeutics Stock (ABEO): Why The Price Fell Today
- The stock price of Abeona Therapeutics Inc (NASDAQ: ABEO) fell by over 25% pre-market today. This is why it happened.
- 12/17/2021
|
Down 15.2% in 4 Weeks, Here's Why Abeona Therapeutics (ABEO) Looks Ripe for a Turnaround
- Abeona Therapeutics (ABEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 11/19/2021
|
Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit
- NEW YORK and CLEVELAND, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., M.B.A., Chief Executive Officer of Abeona, is scheduled to present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021, at 3:30 p.m. ET.
- 10/21/2021
|
Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses
- NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021. The presentations include a poster presentation on the long-term wound healing and pain relief data from the Phase 1/2a EB-101 trial at the 2021 Pediatric Dermatology Research Alliance (PeDRA) Annual Conference, held virtually October 14-15, 2021; and an oral presentation on the pivotal trial of the Company's investigational AAV-based gene therapy ABO-102 in MPS IIIA at the virtual 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), October 19-22, 2021.
- 10/13/2021
|
Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality
- NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vice President, Head of Quality. Mr. Voss, who has been advising the Company as a consultant, will now serve in a leadership role to further strengthen Abeona's quality system and oversee all quality functions.
- 10/12/2021
|
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings
- Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board
- 09/21/2021
|
Abeona Therapeutics to Present at Upcoming Investor Conferences
- NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company's management will present and conduct one-on-one meetings at the following virtual investor conferences:
- 09/07/2021
|
Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer
- NEW YORK and CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr as Chief Financial Officer and Principal Financial Officer, effective immediately. Mr. Carr had served as Abeona's Chief Accounting Officer since January 2019.
- 08/10/2021
|
Abeona Therapeutics Reports Second Quarter Financial Results
- Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL™ study
- 07/28/2021
|
Abeona Stock Gains As It Concludes Type B Meeting With FDA For MPS IIIA Gene Therapy
- Abeona Therapeutics Inc (NASDAQ: ABEO) has completed a Type B meeting with the FDA regarding the pivotal trial for its ABO-102 gene therapy for Sanfilippo syndrome type A (MPS IIIA). ABO-102 is currently being evaluated in the single-arm Transpher A study in patients with MPS IIIA.
- 07/28/2021
|
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
- New data from Phase 1/2 Transpher A study presented at 16th International Symposium on MPS and Related Diseases New data from Phase 1/2 Transpher A study presented at 16th International Symposium on MPS and Related Diseases
- 07/26/2021
|
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystrophic Epidermolysis Bullosa
- NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal Phase 3 VIITAL™ study of its investigational EB-101 treatment for recessive dystrophic epidermolysis bullosa (RDEB) at UMass Memorial Medical Center in Worcester, MA.
- 07/23/2021
|
Abeona Unveils Additional Data From Gene Therapy Trial For Rare Connective Tissue Disorder
- Abeona Therapeutics Inc (NASDAQ: ABEO) has announced updated data from Phase 1/2a trial for up to six years following treatment with EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The data showed that investigator assessment of wound healing of over 50% from baseline was present in 69% of treated wounds (n=18/26) at three years, 93% (n=14/15) at four years, 80% (n=12/15) at five years, and 80% (n=4/5) at six years.
- 07/07/2021
|
Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting
- NEW YORK and CLEVELAND, July 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced updated Phase 1/2a clinical trial results up to six years following treatment with Abeona's investigational EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The data showed that investigator assessment of wound healing of 50% or greater from baseline was present in 69% of treated wounds (n=18/26) at 3 years, 93% (n=14/15) at 4 years, 80% (n=12/15) at 5 years, and 80% (n=4/5) at 6 years. The results were reported in a poster, titled “Long-Term Healing, Pain Reduction, and Patient-Reported Outcomes in Recessive Dystrophic Epidermolysis Bullosa Following EB-101 Treatment of Large, Chronic Wounds,” at the Society for Pediatric Dermatology (SPD) 46th Annual Meeting.
- 07/07/2021
|
Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference
- NEW YORK and CLEVELAND, June 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 a.m. ET.
- 06/02/2021
|
Best Penny Stocks in 2021 So Far? Here's 4 You Should Check Out
- These penny stocks are pushing up, should you add them to your watchlist? The post Best Penny Stocks in 2021 So Far?
- 05/26/2021
|
Abeona Therapeutics Inc. (ABEO) CEO Michael Amoroso on Q1 2021 Results - Earnings Call Transcript
- Abeona Therapeutics Inc. (ABEO) CEO Michael Amoroso on Q1 2021 Results - Earnings Call Transcript
- 05/25/2021
|
Abeona Therapeutics Reports First Quarter Financial Results
- Patient enrollment ongoing for EB-101 pivotal Phase 3 VIITAL™ study
- 05/18/2021
|
3 Penny Stocks That Wall Street Wants You To Buy Now
- Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.
- 04/21/2021
|
7 Penny Stocks That May Not Be Penny Stocks For Long
- Many penny stocks are destined for bankruptcy, but there are some that will survive. Wall Street thinks these companies are undervalued.
- 04/21/2021
|
Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting
- NEW YORK and CLEVELAND, April 20, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data from its preclinical research will be highlighted during an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held virtually from May 1-7, 2021.
- 04/20/2021
|
Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors
- New board members add a wealth of experience in clinical development and manufacturing of cell therapy and gene therapy products New board members add a wealth of experience in clinical development and manufacturing of cell therapy and gene therapy products
- 04/19/2021
|
Abeona Therapeutics Inc. (ABEO) CEO Michael Amoroso on Q4 2020 Results - Earnings Call Transcript
- Abeona Therapeutics Inc. (ABEO) CEO Michael Amoroso on Q4 2020 Results - Earnings Call Transcript
- 03/25/2021
|
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
- Refreshed board to bring fresh perspectives, relevant expertise and diverse experience Refreshed board to bring fresh perspectives, relevant expertise and diverse experience
- 03/25/2021
|
Abeona Therapeutics (ABEO) Reports Q4 Loss, Lags Revenue Estimates
- Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -88.89% and -45.95%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/24/2021
|
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
- Fourth patient treated in pivotal Phase 3 VIITAL™ study of EB-101 in RDEB after successful Type B meeting with FDA
- 03/24/2021
|
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
- NEW YORK, March 23, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Abeona Therapeutics Inc. (NASDAQ: ABEO). If you are a shareholder of Abeona Therapeutics Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: http://pjlfirm.com/abeona-therapeutics-inc/ You may also contact Robert H.
- 03/23/2021
|
Week 9 MDA Breakout Stocks - March 2021: Short-Term Picks To Give You An Edge
- Week 9 MDA Breakout Stocks - March 2021: Short-Term Picks To Give You An Edge
- 02/28/2021
|
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
- NEW YORK and CLEVELAND, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 11:20 am EST.
- 02/22/2021
|
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona's ABO-102 Gene Therapy
- In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained reductions in disease-specific biomarkers, denoting clear biologic effects
- 02/12/2021
|
Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
- NEW YORK and CLEVELAND, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it will host a live webinar for the investment community on Tuesday, February 16, 2021 at 1:00 p.m. EST to review clinical data on the company's investigational AAV-based gene therapies ABO-102 and ABO-101 presented at the 17th Annual WORLDSymposium™.
- 02/02/2021
|
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Clinical trial amendment successfully completed for co-primary endpoints of partial wound closure and mean pain reduction Clinical trial amendment successfully completed for co-primary endpoints of partial wound closure and mean pain reduction
- 01/25/2021
|
Do Options Traders Know Something About Abeona (ABEO) Stock We Don't?
- Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
- 01/12/2021
|
Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™
- NEW YORK and CLEVELAND, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing new interim results from its ABO-102 Phase 1/2 Transpher A study for MPS IIIA and ABO-101 Phase 1/2 Transpher B study for MPS IIIB have been accepted for platform oral presentations during the late-breaking abstract session at the 17th Annual WORLDSymposium™ being held February 8-12, 2021.
- 12/21/2020
|
Why This Abeona Therapeutics Analyst Is Turning Bullish After Q3 Print
- Abeona Therapeutics Inc's (NASDAQ: ABEO) stock does not reflect the company's in-house manufacturing capabilities and pipeline, according to Cantor Fitzgerald. The Abeona Therapeutics Analyst: Kristen Kluska upgraded Abeona Therapeutics from Neutral to Overweight while maintaining the price target at $4.
- 11/11/2020
|
Abeona Therapeutics Reports Third Quarter Financial Results
- Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET
- 11/09/2020
|
Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
- NEW YORK and CLEVELAND, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Senior Vice President and Chief Commercial Officer at Abeona, has been promoted to Chief Operating Officer and will serve as the Company's principal executive and operating officer, effective November 1, 2020. In this newly created role at Abeona, Mr. Amoroso's responsibilities will broaden to include oversight and leadership of all operations; including but not limited to, research and clinical development, regulatory, medical, commercial, corporate affairs and business development.
- 10/27/2020
|
OXGENE Introduces TESSA Technology for Robust and Reproducible AAV Manufacture at Scale
- OXGENE™, a biotechnology company designing and developing scalable gene therapy technologies, has today announced the launch of its scalable, plasmid-
- 09/22/2020
|
Abeona Therapeutics (ABEO) Investor Presentation - Slideshow
- The following slide deck was published by Abeona Therapeutics Inc. in conjunction with this event..
- 09/11/2020
|
Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease
- NEW YORK and CLEVELAND and DALLAS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, and Taysha Gene Therapies, a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease, today announced that they have entered into license and inventory purchase agreements for ABO-202, an adeno-associated virus (AAV) gene therapy for CLN1 disease (also known as infantile Batten disease). The agreements grant Taysha worldwide exclusive rights to intellectual property developed by scientists at the University of North Carolina at Chapel Hill (UNC) and Abeona, and Abeona know-how relating to the research, development, and manufacture of ABO-202. The therapy was originally developed in the lab of Steven Gray, Ph.D., Associate Professor at UT Southwestern Medical Center (formerly with UNC) and Chief Scientific Advisor for Taysha Gene Therapies. Abeona continued to progress the program, including development of the Phase 1/2 clinical trial protocol and manufacturing process, and received FDA clearance of its Investigational New Drug (IND) Application for a Phase 1/2 clinical trial that is anticipated to enter the clinic in 2021. Under the terms of the agreement, Taysha will make initial cash payments to Abeona of $7 million, comprised of a $3 million upfront license fee and $4 million inventory purchase price, including GMP-sourced CLN1 plasmid from Abeona. In addition, Abeona is eligible to receive up to $56 million from Taysha upon the achievement of certain clinical, regulatory and sales milestones, plus high single-digit royalties on net sales of Taysha’s CLN1 product.“We are excited to partner with Taysha in their further development of a potential treatment for children living with Batten disease,” said João Siffert, M.D., Chief Executive Officer of Abeona. “At the same time, these agreements allow Abeona to continue to focus its resources on advancing its key clinical programs in RDEB, MPS IIIA and MPS IIIB towards Biologics License Application submissions with the goal of providing safe and effective gene and cell therapies to patients who currently have no approved treatment options.”“CLN1 is a progressive monogenic CNS disease with significant unmet medical need, and we believe the ABO-202 data generated thus far demonstrate great translational potential and offer hope to children suffering from this devastating disorder,” said RA Session II, President, Chief Executive Officer and Founder of Taysha. “We are excited to continue working closely with Dr. Gray to rapidly advance this promising gene therapy into the clinic.”ABO-202 is a one-time, self-complementary AAV (serotype 9) gene therapy designed to deliver a functional copy of the palmitoyl-protein thioesterase 1 (PPT1) gene. Preclinical studies in a CLN1 animal model demonstrated that ABO-202 normalized survival and led to improvement of neurological function in affected mice. The therapy has been granted Orphan Drug and Rare Pediatric Disease designations by the U.S. Food and Drug Administration (FDA) and has received Orphan Medicinal Product Designation from the European Medicines Agency.About CLN1 disease (Infantile Batten disease) CLN1 disease, also known as Infantile Neuronal Ceroid Lipofuscinosis or infantile Batten disease, is a rapidly progressing rare lysosomal storage disease with no approved treatment. It primarily affects the central nervous system and typically manifests during the first year of life with vision impairment that can progress to blindness, progressive motor and cognitive decline, seizures and ultimately early death. The underlying cause of the disorder is a defect in the PPT1 gene that encodes the enzyme of the same name, resulting in the accumulation of lipopigments within cells, leading to neuroinflammation and neurodegeneration. Some patients with CLN1 disease develop symptoms later in childhood or in adulthood; these variants are called late-infantile, juvenile, or adult-onset CLN1.About ABO-202 ABO-202 is a novel, one-time gene therapy for CLN1 disease, a rapidly progressing rare lysosomal storage disease with no approved therapy. ABO-202 delivers a functional copy of the PPT1 gene to address the underlying gene and enzyme deficiency that leads to abnormal buildup of lipopigments and results in neuroinflammation and neurodegeneration.About Abeona Therapeutics Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company’s portfolio of AAV-based gene therapies also features ABO-201 for CLN3 disease. Abeona’s novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona’s fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies. For more information, visit www.abeonatherapeutics.com.About Taysha Gene Therapies Taysha Gene Therapies is a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease. We are focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. We were founded in partnership with The University of Texas Southwestern Medical Center, or UT Southwestern, to develop and commercialize transformative gene therapy treatments. Together with UT Southwestern, we are advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. By combining our management team’s proven experience in gene therapy drug development and commercialization with UT Southwestern’s world-class gene therapy research capabilities, we believe we have created a powerful engine to develop transformative therapies to dramatically improve patients’ lives. More information is available at www.tayshagtx.com.Forward-Looking Statements This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include statements about the Company’s clinical trials and its products and product candidates, future regulatory interactions with regulatory authorities, as well as the Company’s goals and objectives. We have attempted to identify forward looking statements by such terminology as “may,” “will,” “believe,” “estimate,” “expect,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to the potential impacts of the COVID-19 pandemic on our business, operations, and financial condition, continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the outcome of any future meetings with the U.S. Food and Drug Administration or other regulatory agencies, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.Abeona Therapeutics Contacts:Investors: Greg Gin VP, Investor Relations Abeona Therapeutics +1 (646) 813-4709 ggin@abeonatherapeutics.comMedia: Scott Santiamo Director, Corporate Communications Abeona Therapeutics +1 (718) 344-5843 ssantiamo@abeonatherapeutics.comTaysha Gene Therapies Contacts:Company: Niren Shah, PharmD, MBA Taysha Gene Therapies Nshah@tayshagtx.comMedia: Carolyn Hawley Canale Communications carolyn@canalecomm.com
- 08/17/2020
|
Genomic Medicine: Summer 2020 Update
- FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.
- 08/13/2020
|
State Street Corp Increases Position in Abeona Therapeutics Inc (NASDAQ:ABEO)
- State Street Corp raised its position in Abeona Therapeutics Inc (NASDAQ:ABEO) by 55.4% during the first quarter, HoldingsChannel reports. The firm owned 950,322 shares of the biopharmaceutical company’s stock after buying an additional 338,756 shares during the quarter. State Street Corp’s holdings in Abeona Therapeutics were worth $1,996,000 as of its most recent SEC filing. […]
- 08/11/2020
|
Abeona Therapeutics annonce ses résultats financiers et mises à jour du deuxième trimestre
- Des patients supplémentaires ont reçu des doses dans le cadre des programmes cliniques sur l'EBDR, le MPS IIIA et le MPS IIIB Alignement général par...
- 08/11/2020
|
Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
- Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs General alignment with CHMP on plans for EU registration of ABO-102 for MPS IIIAData from RDEB and MPS III programs presented at recent medical meetingsStrengthened leadership team with appointment of experienced Chief Commercial Officer and two independent Board members Conference call on Tuesday, August 11, 2020 at 8:30 a.m. ETNEW YORK and CLEVELAND, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced financial results for the second quarter 2020 and recent business progress.“During the past several months, Abeona has delivered on our goals in clinical development, manufacturing, and regulatory affairs toward bringing urgently needed treatments to patients with RDEB and MPS III,” said João Siffert, M.D., Chief Executive Officer of Abeona. “Notably, new patients have been treated in our RDEB and MPS IIIA clinical programs, and we expect additional patient enrollment across our clinical programs in the coming weeks. Concurrent with the increased clinical activities, we resumed internal manufacturing operations at our Cleveland campus in June. We have made significant advancements in process development for retrovirus and AAV manufacturing in-house, anticipated to start in late-2020 and early-2021, respectively. In addition, we recently reached general alignment with the CHMP on our proposed path toward a European marketing authorization application for ABO-102 in MPS IIIA, anticipated in 2023. Looking ahead to the potential commercial launches of EB-101 in late-2022 and ABO-102 the following year, we have also strengthened our leadership team, bringing on board a Chief Commercial Officer with significant relevant experience and expertise.”Second Quarter and Recent HighlightsEB-101 (Autologous, Gene-Corrected Cell Therapy) * A second patient was treated in Abeona’s EB-101 pivotal Phase 3 VIITAL™ study for recessive dystrophic epidermolysis bullosa (RDEB) after enrollment resumed in June 2020 following a pause due to the COVID-19 pandemic. Additional patients are expected to be treated in the coming weeks, with completion of enrollment in the VIITAL study expected in early-2021. * Two posters were presented at the Society for Pediatric Dermatology 45th Annual Meeting. The first poster highlighted data showing that EB-101 treatment of large RDEB wounds resulted in up to five years of durable healing, which was associated with long-term pain relief. A separate poster characterized the significant disease burden of RDEB on patients and their families.ABO-102 and ABO-101 (AAV-based Gene Therapies) * In July 2020, Abeona held a kick-off meeting under the European Medicines Agency’s (EMA) PRIority MEdicines (PRIME) program, which included members of the Committee for Advanced Therapies (CAT) and the Committee for Medicinal Products for Human Use (CHMP) of the EMA. The Company presented its plan toward registration of ABO-102 for MPS IIIA (Sanfilippo syndrome type A), taking advantage of the PRIME designation that offers a path for accelerated assessment of promising therapies targeting unmet medical needs. Based on the PRIME meeting, along with previous input from the CHMP and the Pediatric Committee (PDCO) of the EMA, Abeona anticipates submitting a marketing authorization application for EU conditional approval of ABO-102 for MPS IIIA in 2023. The Company continues to seek guidance from the FDA on the U.S. regulatory path for ABO-102 in MPS IIIA, but acknowledges that the FDA is currently focused on matters related to COVID-19 and other life-threatening conditions, as reflected in its issued guidance in May 2020. * Total enrollment to date in the ABO-102 Transpher A study for MPS IIIA is 17 patients, including 11 patients dosed in cohort 3. Total enrollment to date in the ABO-101 Transpher B study for MPS IIIB (Sanfilippo syndrome type B) is 9 patients, including 2 patients dosed in cohort 3. Abeona anticipates completing enrollment in both the Transpher A and Transpher B studies by the end of 2020. * Updated positive interim data from the Transpher A and Transpher B studies were presented at the American Society of Gene & Cell Therapy 23rd Annual Meeting. The findings support previously reported data showing preservation of neurocognitive skills among three young patients treated in dose cohort 3 of the Transpher A study. Improvements in multiple disease-specific biomarkers, denoting clear biologic effects, and a favorable safety profile in MPS IIIA and MPS IIIB patients after treatment with ABO-102 and ABO-101, respectively, were observed in both studies.Manufacturing Activities * In June 2020, Abeona fully resumed operations at its state-of-the-art GMP manufacturing facility in Cleveland, Ohio, manufacturing EB-101 drug product for the Phase 3 VIITAL™ study. The Company initiated process development at the facility that will enable production of the retrovirus used for EB-101 manufacture, allowing for increased control of the supply chain and product quality, as well as reduced costs. Abeona also resumed process development activities to enable in-house manufacturing of commercial supply of ABO-101 and ABO-102.Corporate Update * The Company further strengthened its leadership team with the appointment of Michael Amoroso as Chief Commercial Officer, and the addition of George Migausky and Paul Mann as independent members of its Board of Directors. In addition to their Board service, Mr. Migausky serves as Chairman of the Company's Audit Committee and Mr. Mann serves as a member of the Audit Committee.Second Quarter Financial ResultsCash, cash equivalents and short-term investments totaled $107.9 million as of June 30, 2020, compared to $129.3 million as of December 31, 2019. Net cash used in operating activities was $9.5 million for the second quarter 2020.Research and development (R&D) spending was $6.1 million for the second quarter of 2020 and $12.9 million for the six months ended June 30, 2020, compared to $16.3 million and $28.0 million in the comparable periods in 2019. The decrease in R&D expenses was primarily due to decreased manufacturing, clinical and non-clinical development activities arising from the effects of the COVID-19 pandemic, and cost savings associated with the decision to internally manufacture retrovirus for the EB-101 program.General and administrative (G&A) expenses were $5.5 million for the second quarter of 2020 and $12.0 million for the six months ended June 30, 2020, compared to $5.6 million and $11.3 million in the comparable periods in 2019. The increase in G&A expenses for the six months ended June 30, 2020 was largely due to increases in salary and related costs partially offset by decreased professional fees.Net loss was $13.0 million for the second quarter of 2020 and $61.2 million for the six months ended June 30, 2020, compared to net loss of $23.9 million and $42.5 million for the comparable periods in 2019.Conference Call DetailsAbeona Therapeutics will host a conference call and webcast tomorrow, Tuesday, August 11, 2020 at 8:30 a.m. ET, to discuss its second quarter 2020 financial results and provide an update on the company's business. To access the call, dial 844-369-8770 (U.S. toll-free) or 862-298-0840 (international) and provide conference ID 18965539 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona’s website at www.abeonatherapeutics.com. The archived webcast replay will be available for 30 days following the call.About Abeona Therapeutics Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company’s portfolio of AAV-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Abeona’s novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona’s fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies. For more information, visit www.abeonatherapeutics.com. Forward-Looking Statements This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include statements about the Company’s clinical trials and its products and product candidates, future regulatory interactions with regulatory authorities, as well as the Company’s goals and objectives. We have attempted to identify forward looking statements by such terminology as “may,” “will,” “believe,” “estimate,” “expect,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements.
- 08/10/2020
|
Bodies of Marines and sailor recovered from the seafloor off San Clemente Island
- Families were notified Friday by visits from Marine Corps officers and chaplains. They will get a chance to see their loved ones during an “honorable carry” at Naval Base San Diego as N…
- 08/08/2020
|
Navy recovery for eight servicemen and seafaring military vehicle to start soon
- The diving and salvage ship is expected to arrive within a few days.
- 08/06/2020
|
Military Finds Vehicle That Sank in a Training Incident That Killed 8 Marines and a Sailor
- The US military has identified the location of the AAV that sank last week off the California coast, killing eight Marines and one sailor.
- 08/05/2020
|
Marines find human remains, vehicle that sunk in California training accident
- The Marines Corps has found the amphibious assault vehicle (AAV) that sank off the coast of Southern California last week, killing nine service members, the service said Tuesday.
- 08/04/2020
|
Did Hedge Funds Make The Right Call On Abeona Therapeutics Inc (ABEO) ?
- The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
- 08/04/2020
|
Global Epidermolysis Bullosa Pipeline 2020: Drugs, Companies, Clinical Trials, R&D Updates, Status and Outlook - ResearchAndMarkets.com
|
Seven marines and sailor presumed dead after amphibious vehicle sinks
- The 15th Marine Expeditionary Unit tweeted early Sunday that the search and rescue mission for 8 missing service members off the coast of Southern California had switched to recovery.
- 08/02/2020
|
Assenagon Asset Management S.A. Sells 14,143 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO)
- Assenagon Asset Management S.A. lessened its position in Abeona Therapeutics Inc (NASDAQ:ABEO) by 16.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 74,492 shares of the biopharmaceutical company’s stock after selling 14,143 shares during the quarter. Assenagon Asset Management S.A. owned 0.09% of […]
- 08/02/2020
|
Search and rescue ship joins hunt for eight military service members
- The Marines have limited the use of amphibious assault vehicles on Friday after one sank in 600 feet of water near San Clemente Island, California. One Marine is dead and others missing.
- 08/01/2020
|
U.S. Marine Corps: AAV Commander Course Navigates Through Pendleton
- During the course, students will learn AAV maintenance, orders and reports, navigation, tactics and gunnery.
- 07/31/2020
|
A US Marine is dead and 8 service members are missing after an amphibious assault vehicle sank off the coast of California
|
A Fake Raid, A Fake Village And A Sinking Track
- A detailed look travelling inside an AAV built to go from sea to shore.
- 07/30/2020
|
The Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 Funding
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 27)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)
Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...
- 07/28/2020
|
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremia
- 4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, annou
- 07/27/2020
|
Forge Biologics Launches with $40 Million Series A Financing to Manufacture and Develop Gene Therapies
- Press Release Forge Biologics, a viral vector gene therapy manufacturing and development company with the dual platform of CDMO capabilities and the development of proprietary gene therapy products, today announced the closing of a $40 million Series A financing led...
- 07/21/2020
|
Critical Review: Abeona Therapeutics (NASDAQ:ABEO) versus Cyclerion Therapeutics (NASDAQ:FBRX)
- Abeona Therapeutics (NASDAQ:ABEO) and Cyclerion Therapeutics (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability. Analyst Ratings This is a breakdown of current recommendations for Abeona Therapeutics and Cyclerion Therapeutics, […]
- 07/19/2020
|
Abeona Therapeutics (NASDAQ:ABEO) Given “Buy” Rating at HC Wainwright
- Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Monday, AnalystRatings.com reports. They presently have a $11.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 265.45% from the stock’s current price. ABEO has been the subject […]
- 07/13/2020
|
AQR Capital Management LLC Purchases New Shares in Abeona Therapeutics Inc (NASDAQ:ABEO)
- AQR Capital Management LLC purchased a new stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 90,742 shares of the biopharmaceutical company’s stock, valued at approximately $191,000. AQR Capital Management LLC owned approximately 0.11% of Abeona […]
- 07/12/2020
|
Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
- EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEBLiterature review of 65 studies confirms and expands.
- 07/10/2020
|
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 9)
Affimed NV (NASDAQ: AFMD)...
- 07/10/2020
|
Abeona Restarts Enrollment in Connective Tissue Disorder Study
- Abeona (ABEO) restarts patient enrollment in phase III VIITAL study of EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.
- 07/09/2020
|
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
- NEW YORK and CLEVELAND, July 09, 2020 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Michael.
- 07/09/2020
|
3 “Perfect 10” Healthcare Stocks That Have Plenty Of Growth On Tap
- Stocks Analysis by Investing Insights covering: ChemoCentryx Inc, United Therapeutics Corporation, Axsome Therapeutics Inc. Read Investing Insights 's latest article on Investing.com
- 07/09/2020
|
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical programs, highlighted by the restart of patient enrollment in the Company’s pivotal Phase 3 VIITAL™ study of EB-101, its autologous, gene-corrected cell therapy, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Enrollment in the VIITAL™ study at Stanford University Medical Center was paused in March 2020 in order to redirect healthcare resources to COVID-19 patients and to ensure the safety of study participants and site staff.
- 07/08/2020
|
With Its Film Fest Postponed by the Pandemic, Rare-Disease Group Starts Its Own Streaming Channel
- Rare Outreach Coalition has launched The Disorder Channel to showcase rare disease films and videos for free on Roku® and Amazon Fire TV.
- 07/08/2020
|
Here's Why We're Watching Abeona Therapeutics's (NASDAQ:ABEO) Cash Burn Situation
- We can readily understand why investors are attracted to unprofitable companies. For example, although...
- 07/03/2020
|
Advantage Oil & Gas Ltd. (TSE:AAV) Receives Consensus Rating of “Buy” from Analysts
- Shares of Advantage Oil & Gas Ltd. (TSE:AAV) (NYSE:AAV) have been assigned a consensus rating of “Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective […]
- 06/28/2020
|
Charity shops see flood of designer goods post-lockdown
- There are already a bundle of designer bargains to be had at DEBRA stores, with locals donating items ranging from Michael Kors shoes to Diane von Furstenberg dresses.
- 06/26/2020
|
Colin Farrell supports 'brave' friend with rare skin disease from LA home
- The Hollywood hunk praised his friend Emma Fogarty who completed a gruelling walking challenge to raise much needed funds for DEBRA Ireland
- 06/26/2020
|
National Bank Financial Lowers Advantage Oil & Gas (TSE:AAV) Price Target to C$3.00
- Advantage Oil & Gas (TSE:AAV) (NYSE:AAV) had its price target reduced by National Bank Financial from C$3.25 to C$3.00 in a report issued on Wednesday, BayStreet.CA reports. The brokerage presently has an “outperform” rating on the stock. National Bank Financial’s price target would suggest a potential upside of 82.93% from the company’s previous close. AAV […]
- 06/26/2020
|
Colin Farrell supports ‘brave' friend with rare skin disease in charity bid
- The actor cycled 36km in support of Emma Fogarty, who crossed the finish line following a month-long assisted charity walk on Thursday.
- 06/25/2020
|
Colin Farrell supports ‘brave’ friend with rare skin disease in charity bid - Evening Telegraph
- Hollywood star Colin Farrell supported an Irish woman with a rare skin disease as she completed a gruelling charity challenge on Thursday.
- 06/25/2020
|
Colin Farrell supports ‘brave’ friend with rare skin disease in charity bid - Evening Express
- Hollywood star Colin Farrell supported an Irish woman with a rare skin disease as she completed a gruelling charity challenge on Thursday.
- 06/25/2020
|
ERYTECH extends its cash horizon by implementing a convertible bond financing | MarketScreener
|
Hedge Funds Still Crazy About Abeona Therapeutics Inc (ABEO)?
- Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
- 06/23/2020
|
Bayer : contributes an additional 50 million units of treatment to the World Federation of Hemophilia Humanitarian Aid Program | MarketScreener
|
People with A Blood group at higher risk of covid-19: Study
- The researchers conducted a genomewide association study involving 1980 patients with Covid-19 .The scientists found studying patients with Covid-19 with respiratory failure found a potential involvement of the ABO blood-group system
- 06/19/2020
|
Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting
- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to its clinical program for recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the upcoming Society for Pediatric Dermatology (SPD) 45th Annual Meeting, to be held virtually during July 10-12, 2020. RDEB is a rare connective tissue disorder without an approved treatment, in which patients suffer from severe epidermal wounds that severely impact their lives. The first abstract features a more detailed examination than previously disclosed of data on long-term pain relief following durable healing of wounds in RDEB patients treated with EB-101 in a Phase 1/2 study.
- 06/18/2020
|
Cowen & Co. Maintains a Buy Rating on IVERIC bio (ISEE) - Markets
- Cowen & Co. analyst Ken Cacciatore maintained a Buy rating on IVERIC bio (ISEE – Research Report) on June 15
- 06/17/2020
|
4D Molecular Therapeutics Announces New Agreement With Cystic Fibrosis Foundation | | IT Business Net
- EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, today announced a
- 06/17/2020
|
Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors
- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced Board of Director appointments that strengthen and expand the Company’s leadership. George Migausky and Paul Mann were appointed as independent directors, effective June 17, 2020. In addition to their Board service, Mr. Migausky will serve as Chairman of the Company's Audit Committee and Mr. Mann will serve as a member of the Audit Committee.
- 06/17/2020
|
4D Molecular Therapeutics Announces New Agreement With Cystic Fibrosis Foundation
- 4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, today
- 06/17/2020
|
AGTC to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020
- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene
- 06/16/2020
|
Fox Corp. In “Very, Very Early” Talks With NFL On Rights Reup, COO John Nallen Says, Labeling Cost Critique “Absurd”
- Fox Corp. COO John Nallen confirmed the company is in “very, very early discussions” with the NFL about renewing its rights deal with the league, a closely watched process that he said …
- 06/16/2020
|
4D Molecular Therapeutics Raises $75 Million in Series C Financing
- 4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, annou
- 06/16/2020
|
Advantage Oil & Gas Ltd. (TSE:AAV) Director Acquires C$31,200.00 in Stock
- Advantage Oil & Gas Ltd. (TSE:AAV) (NYSE:AAV) Director Ronald A. Mcintosh purchased 15,000 shares of the company’s stock in a transaction on Monday, June 8th. The stock was bought at an average price of C$2.08 per share, for a total transaction of C$31,200.00. Following the completion of the purchase, the director now directly owns 92,286 […]
- 06/14/2020
|
BIO: Audentes CEO Holles on keeping the biotech spirit
- When Astellas closed its $3 billion buyout of Audentes Therapeutics, the J.P. Morgan conference crowd was full of “backhanded congratulations.” They offered Natalie Holles, then the newly minted CEO of Audentes, their kudos along with horror stories of biotechs that had been subsumed by Big Pharma and lost their spunk.
- 06/11/2020
|
Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports
- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential
- 06/11/2020
|
EN DIRECT DES MARCHES : Sanofi, Peugeot, Iliad, Soitec, Europlasma, Eli Lilly, Just Eat Takeaway, Tesla, Generali...
|
|
|
Global Leukemia Therapeutics Market Forecast and Opportunities to 2025 - ResearchAndMarkets.com
|
Muscular disorder treatment might provide basis for COVID-19 vaccine
- University of Florida researchers on Wednesday announced plans to repurpose a gene therapy approach used to treat rare neuromuscular diseases for a potential vaccine against COVID-19.
- 06/10/2020
|
Repligen: Management Gambled With 2020 Guidance But Long-Term Growth Story Looks Compelling (NASDAQ:RGEN)
- Repligen develops and sells bioprocessing technologies and systems involved in the manufacturing of biological drugs. The company operates within a high growth,
- 06/10/2020
|
Xconomy: Akouos Aims for an IPO to Advance Hearing Loss Gene Therapy to Clinic
- Hearing loss can stem from a variety of reasons, but in rare cases it’s caused by genetic defects. Akouos is developing a gene therapy to address these
- 06/08/2020
|
Incredible flying taxi takes to the skies – and you could hail one by 2023
- Chinese technology firm EHang has developed a flying taxi called EHang 216, that could be ready to accept customers in just three years
- 06/08/2020
|
Edited Transcript of ABEO earnings conference call or presentation 7-May-20 12:30pm GMT
- Q1 2020 Abeona Therapeutics Inc Earnings Call
- 06/08/2020
|
ChemoCentryx: Avacopan's Attractive Value Proposition (NASDAQ:CCXI)
- ChemoCentryx management is still delivering strong execution. Despite the recent announcement that the LUMINA-1 trial failed to meet its primary endpoint, there
- 06/08/2020
|
Colin Farrell hails friend with rare disease as she preps for charity challenge
- Farrell and Irish rugby captain Johnny Sexton have both sent video messages to Emma Fogarty who suffers from Epidermolysis Bullosa
- 06/04/2020
|
Colin Farrell hails charity challenge by brave friend with rare...
- Emma Fogarty, who has a disorder known as butterfly skin, is trying to complete 36km to mark her 36th birthday later this month.
- 06/04/2020
|
Colin Farrell hails charity challenge by brave friend with rare skin disease
- Emma Fogarty, who has a disorder known as butterfly skin, is trying to complete 36km to mark her 36th birthday later this month.
- 06/04/2020
|
Somebody tell Mesoblast we get the message
- Mesoblast has now put out at least nine announcements since April 9 covering the same potential treatment for COVID-19.
- 06/03/2020
|
Is Abeona Therapeutics (ABEO) Outperforming Other Medical Stocks This Year?
- Is (ABEO) Outperforming Other Medical Stocks This Year?
- 05/28/2020
|
Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
- NEW YORK and CLEVELAND, May 28, 2020 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D.,.
- 05/28/2020
|
Big gene therapy names line up behind experimental Covid-19 vaccine
- An early stage vaccine is drawing interest from James Wilson, a gene therapy pioneer, as well as AveXis, the gene therapy unit of the drug giant Novartis.
- 05/28/2020
|
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
- Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Surface Oncology Inc (...
- 05/24/2020
|
City of Hope Physicians/Scientists Lead Multiple, Innovative COVID-19 Research Projects
- City of Hope’s physician-scientists and basic scientists are using their expertise to attack the deadly coronavirus on multiple research fronts.
- 05/21/2020
|
Gene Therapy Stocks Have Fallen Out Of Favor. Time To Buy?
- Companies that have been able to deliver compelling results have been acquired by big pharma companies (for instance, Spark Therapeutics was acquired by Roche), while others have underperformed, due to large R&D investments and delays in launching revenue-generating products.
- 05/15/2020
|
uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting | MarketScreener
|
Global Regenerative Medicine Markets, 2015-2025 - Impact of COVID-19, Trends & Developments, Competitive Landscape - ResearchAndMarkets.com
|
6 Stock Charts To Watch: AMRS, CYTK, DRNA, LX, MRNA, VAPO
- Stocks Analysis by Harry Boxer covering: SPDR S&P 500, Amyris Inc, BioCryst Pharmaceuticals Inc, Cytokinetics Inc. Read Harry Boxer's latest article on Investing.com
- 05/12/2020
|
Xconomy: Dyno Debuts With Plan, Partnerships for Better Gene Therapy Vectors
- Gene therapies deliver healthy genetic material to patients’ cells to replace a mutated, disease-causing variant. Dyno Therapeutics aims to create better
- 05/11/2020
|
Dyno Therapeutics Emerges from Stealth to Transform Gene Therapy Using Artificial Intelligence
- Dyno Therapeutics Emerges from Stealth to Transform Gene Therapy using Artificial Intelligence
- 05/11/2020
|
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q1 2020 Results - Earnings Call Transcript
- Selecta Biosciences, Inc. (NASDAQ:SELB) Q1 2020 Earnings Conference Call May 07, 2020, 08:30 ET Company Participants Elona Kogan - General Counsel & Corpora
- 05/09/2020
|
Catalent, Inc. (CTLT) CEO John Chiminski on Q3 2020 Results - Earnings Call Transcript
- Catalent, Inc. (NYSE:CTLT) Q3 2020 Earnings Conference Call May 5, 2020 08:15 ET Company Participants Paul Surdez - Vice President, Investor Relations John Chim
- 05/09/2020
|
Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y
- Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.
- 05/08/2020
|
U.S. RESEARCH ROUNDUP-Becton Dickinson, Epam Systems, PayPal Holdings
- Wall Street securities analysts on Friday revised their ratings and price targets on several
U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings.
HIGHLIGHTS
* Becton Dickinson and Co : Citigroup raises price target to $260 from $234
* Carrols Restaurant Group Inc : Craig-Hallum raises to buy from hold; raises target price to $5 from $3.75
* Computer Programs and Systems Inc : Cantor Fitzgerald raises to overweight from neutral
* Epam Systems Inc : Citigroup raises price target to $265 from $245
* PayPal Holdings Inc : Citigroup raises price target to $145 from $131
Following is a summary of research actions on U.S. companies reported by Reuters on Friday. Stock entries are in alphabetical
order.
* Aaron's Inc : Keybanc cuts target price to $55 from $66
* Aaron's Inc : Raymond James cuts target price to $50 from $60
* Aaron's Inc : Stephens raises target price to $45 from $26
* Abeona Therapeutics Inc : RBC cuts target price to $7 from $11
* Acceleron pharma Inc : Credit Suisse raises target price to $123 from $99
* ACI Worldwide Inc : Canaccord Genuity cuts target price to $35 from $44
* Acushnet Holdings Corp : Jefferies raises target price to $25 from $24
* Acushnet Holdings Corp : JP Morgan raises target price to $30 from $27
* Adtran Inc : Cowen and Company raises price target to $13 from $9
* Aeglea Bio Therapeutics Inc : Needham cuts price target to $11 from $14
* Aerie Pharmaceuticals Inc : Citigroup cuts price target to $38 from $39
* Agco Corp : Citigroup cuts price target to $55 from $57
* AIG : KBW raises target price to $36 from $35
* Alaska Air Group Inc : Credit Suisse cuts target price to $51 from $82
* Allison Transmission Holdings Inc : Citigroup raises price target to $39 from $38
* Allscripts Healthcare Solutions : Cantor Fitzgerald cuts PT to $6 from $8
* Alteryx Inc : Guggenheim cuts target price to $130 from $160
* American Airlines : Credit Suisse cuts target price to $4 from $26
* Ameriprise Financial Inc : Credit Suisse raises target price to $165 from $153
* Ameriprise Financial Inc : Piper Sandler raises target price to $150 from $130
* Amerisourcebergen Corp : Baird raises target price to $115 from $109
* Amerisourcebergen Corp : Mizuho raises target price to $90 from $85
* Amtech Systems Inc : Cowen and Company raises target price to $7.50 from $7
* Angi Homeservices Inc : Needham raises target price to $11 from $8
* Ani Pharmaceuticals Inc : Guggenheim cuts target price to $48 from $58
* Ansys Inc : RBC raises target price to $260 from $230
* Anthem Inc : Bernstein raises target price to $357 from $342
* Appian Corp : Cowen and Company raises price target to $44 from $39
* Applied Optoelectronics Inc : D.A. Davidson raises target price to $12 from $10
* Applied Optoelectronics Inc : Piper Sandler raises target price to $10 from $7.50
* Aptiv Plc : Citigroup raises price target to $84 from $67
* ArcelorMittal SA : Keybanc raises target price to $15 from $13
* Arcturus Therapeutics Holdings Inc : Baird raises target price to $44 from $26
* Arcturus Therapeutics Holdings Inc : Guggenheim raises target price to $51 from $41
* Ares Capital Corp : Citigroup raises price target to $15 from $13
* Athersys Inc : Needham cuts price target to $5 from $6
* Atlas Air Worldwide Holdings Inc : Cowen and Company raises PT to $44 from $40
* Avalara Inc : Canaccord Genuity raises target price to $115 from $105
* Avalara Inc : JP Morgan raises target price to $120 from $104
* Avalara Inc : Mizuho raises price target to $120 from $85
* Avalara Inc : Piper Sandler raises target price to $113 from $90
* Avalonbay Communities Inc : Stifel raises target price to $176 from $171
* Avrobio Inc : Guggenheim raises target price to $50 from $49
* Axalta Coating Systems Ltd : RBC raises target price to $21 from $20
* Bausch Health Companies Inc : Piper Sandler cuts target price to $32 from $34
* Beacon Roofing Supply Inc : SunTrust Robinson raises target price to $26 from $24
* Beacon Roofing Supply Inc : Wedbush raises target price to $23 from $16
* Becton Dickinson and Co : Citigroup raises price target to $260 from $234
* Becton Dickinson and Co : Evercore ISI raises target price to $270 from $255
* Beyond Meat Inc : Berenberg raises price target to $125 from $115
* Bill.Com Holdings Inc : Canaccord Genuity raises target price to $65 from $50
* Bill.Com Holdings Inc : Jefferies raises target price to $70 from $45
* Bill.Com Holdings Inc : Keybanc raises target price to $76 from $60
* Bill.Com Holdings Inc : Needham raises target price to $90 from $55
* Biomarin Pharmaceutical Inc : Canaccord Genuity raises PT to $119 from $108
* BJ's Restaurants Inc : Wedbush cuts target price to $32 from $39
* Booking Holdings Inc : Credit Suisse raises target price to $1,810 from $1,790
* Booking Holdings Inc : Jefferies cuts target price to $1300 from $1350
* Booking Holdings Inc : Mizuho cuts price target to $1700 from $1720
* Booking Holdings Inc : RBC raises target price to $1,550 from $1,535
* Booking Holdings Inc : RBC raises target price to $1550 from $1535
* BorgWarner Inc : Citigroup raises price target to $30 from $23
* BorgWarner Inc : Credit Suisse raises target price to $33 from $31
* Bottomline Technologies (De) Inc : Citigroup raises price target to $46 from $43
* Bright Horizons Family Solutions Inc : Citigroup raises PT to $122 from $80
* Brightsphere Investment Group Inc : Evercore ISI raises target to $9 from $6
* Brightsphere Investment Group Inc : KBW raises target price to $9.50 from $7.25
* Brightview Holdings Inc : Credit Suisse cuts target price to $14 from $18
* Brightview Holdings Inc : Jefferies raises target price to $14 from $12
* Cabot Microelectronics Corp : Citigroup cuts price target to $140 from $175
* Cactus Inc : zephirin Group raises price objective to $12 from $8
* Calithera Biosciences Inc : Jefferies raises target price to $9 from $6
* Calyxt Inc : BMO cuts price target to $7 from $13
* Calyxt Inc : BMO cuts to market perform from outperform
* Camping World Holdings Inc : Credit Suisse raises target price to $12 from $11
* Camping World Holdings Inc : JP Morgan raises price target to $11 from $10
* Capstar Financial Holdings Inc : KBW raises target price to $11 from $10.50
* Cargurus Inc : BTIG raises target price to $26 from $23
* Carrols Restaurant Group Inc : Craig-Hallum raises to buy from hold; raises target price to $5 from $3.75
* Castlight Health Inc : Cantor Fitzgerald cuts target price to $1 from $2
* Catasys Inc : Canaccord Genuity raises target price to $36 from $35
* CBRE Group Inc : Evercore ISI cuts target price to $48 from $50
* CBRE Group Inc : KBW cuts target price to $51 from $52
* Centerpoint Energy Inc : Guggenheim raises target price to $26 from $25
* Centerpoint Energy Inc : Keybanc raises target price to $16 from $12
* Centurylink Inc : RBC cuts target price to $10 from $14
* CF Industries Holdings Inc : Citigroup cuts price target to $29 from $31
* CF Industries Holdings Inc : Scotiabank raises target price to $32 from $31
* ChannelAdvisor Corp : Needham raises price target to $14 from $11
* Charles River Laboratories International : Credit Suisse cuts PT to $159 from $162
* Charles River Laboratories International : Evercore ISI ups PT to $176 from $154
* Charles River Laboratories International : Jefferies raises PT to $161 from $139
* Charles River Laboratories International Inc : Citigroup raises price target to $190 from $165
* Chart Industries Inc : zephirin Group raises price objective to $25 from $17
* Charter Communications Inc : Benchmark raises price target to $600 from $523
* Chemours Co : Citigroup raises price target to $13 from $8
* Cimarex Energy Co : MKM Partners raises target price to $34 from $31
* City Holding Co : Stephens cuts target price to $63 from $64.
- 05/08/2020
|
Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates
- Horizon Therapeutics (HZNP) beat on earnings and sales in the first quarter of 2020. The company lifts net sales guidance for the full year.
- 05/07/2020
|
Taysha Gene Therapies Announces Presentations Highlighting Programs and Platform Technologies at the 2020 Annual Meeting of the American Society of Gene and Cell Therapy
- Taysha Gene Therapies Announces Presentations Highlighting Programs and Platform Technologies at #ASGCT20
- 05/07/2020
|
Abeona Therapeutics Reports First Quarter Financial Results and Business Updates
- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced first quarter 2020 financial results, which will be discussed on a conference call scheduled for Thursday, May 7, 2020 at 8:30 a.m. ET. “During these challenging times, our priority remains to ensure the safety of our employees and patients, while supporting continuity of our business and clinical operations,” said João Siffert, M.D., Chief Executive Officer of Abeona. It is our intention to restore full patient access to our clinical programs as soon as possible.
- 05/06/2020
|
Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market 2020 Overview, Manufacturing Analysis, Segmentation, Development Status and Forecast to 2025
- May 02, 2020 (CDN Newswire via Comtex) --
A recent comprehensive study titled Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market 2020...
- 05/02/2020
|
Moving Average Crossover Alert: Abeona Therapeutics
- Abeona Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
- 04/29/2020
|
Top Ranked Momentum Stocks to Buy for April 28th
- Top Ranked Momentum Stocks to Buy for April 28th
- 04/28/2020
|
Asklepios BioPharmaceutical Acquires BrainVectis | FinSMEs
- Asklepios BioPharmaceutical acquired BrainVectis, a Paris, France-based gene therapy company and French National Institute for Health and Medical Research (INSERM) spin-out with expertise and an intellectual property estate for the treatment of neurodegenerative disorders
- 04/27/2020
|
Can Vertex (VRTX) Withstand the Coronavirus Impact on Q1 Earnings?
- On Vertex's (VRTX) first-quarter earnings call, investor focus will be on the sales uptake of its newly-launched CF drug, Trikafta.
- 04/24/2020
|
Can Vertex (VRTX) Withstand the Coronavirus Impact on Q1 Earnings?
- On Vertex's (VRTX) first-quarter earnings call, investor focus will be on the sales uptake of its newly-launched CF drug, Trikafta.
- 04/24/2020
|
Is a Beat in Store for Abeona (ABEO) This Earnings Season?
- Abeona's (ABEO) operating expenses are expected to have increased in the first quarter driven by clinical studies on its lead gene therapy candidate.
- 04/24/2020
|
Abeona Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced it granted options to Brian Pereira, M.D., the newly-appointed Executive Chairman of the Company, to purchase 930,000 shares of Abeona common stock. The stock options have a $2.50 exercise price per share, which is equal to the closing price of Abeona's common stock on the grant date. The options were offered as a material inducement to Dr. Pereira’s appointment as Executive Chairman.
- 04/21/2020
|
Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors
- NEW YORK and CLEVELAND, April 21, 2020 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced appointments of Brian.
- 04/21/2020
|
Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options
- Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
- 04/20/2020
|
Investors Who Bought Abeona Therapeutics (NASDAQ:ABEO) Shares A Year Ago Are Now Down 71%
- The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
- 04/20/2020
|
Dynavax Technologies (DVAX) in Focus: Stock Moves 9.1% Higher
- Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
- 04/17/2020
|
Dynavax Technologies (DVAX) in Focus: Stock Moves 9.1% Higher
- Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
- 04/17/2020
|
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Abeona Therapeutics Inc. for Potential Breach of Fiduciary Duty Claims
- NEW YORK, April 17, 2020 -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Abeona Therapeutics.
- 04/17/2020
|
Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
- Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.
- 04/07/2020
|
Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
- Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
- 04/07/2020
|
Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
- Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
- 04/07/2020
|
Edited Transcript of ABEO earnings conference call or presentation 17-Mar-20 2:00pm GMT
- Q4 2019 Abeona Therapeutics Inc Earnings Call
- 04/05/2020
|
Analysts' Opinions Are Mixed on These Healthcare Stocks: Abeona Therapeutics (ABEO), Teva Pharmaceutical Industries (TEVA) and Capricor Therapeutics (CAPR)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Abeona Therapeutics (ABEO), Teva Pharmaceutical Industries (TEVA) and
- 04/02/2020
|
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Abeona Therapeutics (NASDAQ: ABEO), Teva Pharmaceutical Industries (NYSE: TEVA) and Capricor Therapeutics (NASDAQ: CAPR)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Abeona Therapeutics (
ABEO
–
Research Report
), Teva Pharmaceutical Industries (
TEVA
–
Research Report
) and Capricor Therapeutics (
CAPR
–
Research Report
).
Abeona T
- 04/02/2020
|
RDS.A, ARNC among top premarket gainers
- ION Geophysical (NYSE:IO) +120% on expecting big jump in Q1 revenues.Neptune Wellness Solutions (NASDAQ:NEPT) +47% on receiving health Canada authorization to commercialize natural, plant-based hand s
- 04/02/2020
|
Regenxbio: A Growth Stock For The Coronavirus Bear Market
- Amid this coronavirus bear market, I strongly believe that you should build shares in fundamentally sound companies. Accumulating stocks in a bear market takes
- 04/01/2020
|
uniQure to Participate in Multiple Upcoming Investor Conferences in April | MarketScreener
|
Malonic Acid Market Size, Share 2020 Global Industry Growth Analysis, Segmentation, Trend, Future Demand and Leading Players Updates by Forecast to 2024
- Mar 30, 2020 (The Expresswire) --
Global "Malonic Acid Market" compromises many advantages that have accelerated the adoption of absorption among various...
- 03/30/2020
|
Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic
- The COVID-19 pandemic has created extraordinary challenges across all aspects of healthcare. Above all, we will take every reasonable measure to ensure the safety of our patients and employees, while sustaining our business operations during this uncertain time. Abeona is fully focused on getting through the pandemic by working closely with our clinical trial sites to ensure that patient safety remains paramount.
- 03/27/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The
- 03/18/2020
|
Analysts Conflicted on These Healthcare Names: Abeona Therapeutics (ABEO) and AbbVie (ABBV)
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abeona Therapeutics (ABEO) and AbbVie (ABBV). Abeona
- 03/18/2020
|
Analysts Conflicted on These Healthcare Names: Abeona Therapeutics (NASDAQ: ABEO) and AbbVie (NYSE: ABBV)
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abeona Therapeutics (ABEO
- 03/18/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that investigators at Stanford University Medical Center have treated the first patient in the pivotal phase III VIITAL™ study evaluating EB-101, the Company’s gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). “Treating the first patient in our pivotal Phase III VIITAL™ study is an important achievement for the EB-101 program, now the most advanced gene therapy program in RDEB,” said João Siffert, M.D., Chief Executive Officer.
- 03/17/2020
|
Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates
- On track to treat first RDEB patient in pivotal Phase 3 VIITAL™ study of EB-101 in Q1 2020 Positive interim data from MPS IIIA and MPS IIIB programs presented at.
- 03/16/2020
|
Is Earthstone (ESTE) Likely to Beat Q4 Earnings Estimates?
- Earthstone Energy's (ESTE) fourth-quarter earnings are likely to have been aided by higher oil production.
- 03/10/2020
|
Borough mayor thanks volunteers for supporting their community - The Wokingham Paper
- “I’ve met so many unsung heroes and would like to take this opportunity to thank them for their continued commitment to those less fortunate than ourselves.”
- 02/29/2020
|
Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
- NEW YORK and CLEVELAND, Feb. 26, 2020 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D.,.
- 02/26/2020
|
3 Biotech Stocks That Soared This Week: Are They Buys?
- Can these high-flying biotech stocks keep up their sizzling momentum?
- 02/22/2020
|
The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
- The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
- 02/21/2020
|
EV On-Board Chargers Market Development Status by Top Key Players 2020 Industry Size, Global Share, Professional Analysis, Market Dynamics, Key Barriers, and Forecast to 2026 Says Industry Research.co
- Feb 21, 2020 (The Expresswire) --
EV On-Board Chargers market report includes all the factors that will affect the market trends, drivers and challenges of...
- 02/21/2020
|
US Dollar Flexes Muscles Against Other Currencies: 5 Winners
- The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.
- 02/20/2020
|
Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™
- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that researchers from the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital presented positive interim data from two ongoing Phase I/II clinical trials evaluating ABO-102 and ABO-101, the Company’s investigational gene therapies for MPS IIIA and MPS IIIB, respectively, at WORLDSymposium™. Results from the Transpher A study demonstrated that MPS IIIA patients younger than 30 months treated with ABO-102 in dose cohort 3 continue to show neurocognitive development 18 months to two years after treatment.
- 02/12/2020
|
Investment Analysts' Updated EPS Estimates for February, 11th (ABEO, AEG, AER, AGI, AHH, AIN, ALPMY, AMCRY, AMRX, AMSC)
- Investment Analysts’ updated eps estimates for Tuesday, February 11th: Abeona Therapeutics (NASDAQ:ABEO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $3.25 target price on the stock. According to Zacks, “Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for […]
- 02/11/2020
|
Casinos, Airlines Tumble as Hong Kong Stocks Resume in Punishing Fashion
- The coronavirus outbreak from Wuhan has hit Hong Kong stocks hard as they resume trade. We won't know the impact on mainland listings until next week at the earliest.
- 01/29/2020
|
Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa
- NEW YORK and CLEVELAND, Jan. 21, 2020 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its participation in the.
- 01/21/2020
|
Abeona Therapeutics Announces Issuance of U.S. Patent for AIM™ Capsids
- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States Patent and Trademark Office (USPTO) issued a patent covering next-generation adeno-associated virus (AAV) capsids generated using the University of North Carolina’s (UNC) AIM™ vector platform and that the USPTO allowed the claims of a companion patent application, which will issue in the next several weeks. Both patents are exclusively licensed by the Company from UNC. On January 14, 2020, the USPTO issued UNC’s U.S. Patent No. 10,532,110, entitled “AAV Vectors Targeted to the Central Nervous System.” The patent provides protection for methods of delivering Abeona’s AAV204-based gene therapy vectors to the central nervous system until November 2036.
- 01/15/2020
|
Abeona Therapeutics lance un essai clinique pivot de phase 3 valuant la thrapie gnique EB-101 pour l'pidermolyse bulleuse dystrophique rcessive
- Les inscriptions à l'étude sont ouvertes et la sélection des patients est en cours à l'Université de Stanford La société s'attend à ce qu'un premier...
- 01/13/2020
|
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has received Institutional Review Board (IRB) approval from Stanford University to commence the VIITAL™ study, the Company’s pivotal Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The majority of patients targeted for enrollment have completed the pre-screening process at Stanford, and the Company expects the first patient in the VIITAL™ study to be treated in the first quarter of 2020. “We expect 2020 to be a transformational year at Abeona, and we are proud to start it with the initiation of our pivotal Phase 3 study evaluating EB-101 in RDEB,” said João Siffert, M.D., Chief Executive Officer.
- 01/13/2020
|
FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm
- Investors who purchased the Company's securities between May 31, 2018 and September 23, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 2, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
- 01/02/2020
|
DEADLINE ALERT - Abeona Therapeutics Inc. (ABEO) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: January 2, 2019
- NEW YORK, NY / ACCESSWIRE / January 2, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Abeona Therapeutics Inc. ("Abeona" or "the ...
- 01/02/2020
|
A Base Editing IPO from Beam Therapeutics
- The ability to modify genes may be one of the most promising disruptive technologies there is today. As the general public learns about the potential of gene editing, retail investors will be looking for stocks that provide some exposure to it. In the case of gene editing, there are three stocks that would be considered pure plays on the theme - at least the last time we checked. That would have been last March when we wrote about A Few Updates on the Progress of Gene Editing noting that 'with patents being filed and issued left and right, it’s also starting to look like there is no
- 10/01/2019
|
Boy with skin disease who said I've had enough of life gets 18000 birthday cards
- Thousands of kind-hearted well-wishers were moved by the challenges faced by Rhys Williams, who lives with rare skin condition epidermolysis bullosa.
- 09/20/2019
|
Xconomy: Passage Bio Gets $116M As Wilson, Yamada Team Up On Gene Therapy Again
- Longtime biopharmaceutical executive Tachi Yamada helped keep the work of gene therapy pioneer James Wilson alive 20 years ago when Wilson was mired in
- 02/14/2019
|
Vor Biopharma Completes $42M Series A Financing | FinSMEs
- Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell therapies to treat hematological malignancies, raised $42m
- 02/14/2019
|
10-year highs: Aus shares 0.4% higher at noon
- 08 May 2018 - Market at Midday: ASX200 back at 10-year highs. Retail trade remained steady in March in seasonally adjusted terms, disappointing economists who expected a rise of 0.3 per cent. Federal Budget due at 7.30pm. Platinum Asset Management’s (ASX:PTM) shares are soaring today about 10 per cent higher after it reported a rise in funds under management. IPH (ASX:IPH) the holding company for intellectual property announced a $40 million on market share buy-back. NorthWest Healthcare Property REIT (TSX:NWH.UN) snaps up 10 per cent of Healthscope (ASX:HSO) shares. Click for more.
- 05/08/2018
|
CAR:T - Has biology outpaced the ability to deliver? -
- Experts comment on manufacturing of CAR-T
- 12/08/2017
|
Harry Boxer’s three biotech-stock breakouts to watch
- In focus: Abeona Therapeutics, Ignyta and Spectrum Pharmaceuticals.
- 10/26/2017
|
TXCELL nomme un expert de la thérapie génique à son Conseil scientifique
- (AOF) - TxCell, société de biotechnologies qui développe des immunothérapies cellulaires personnalisées innovantes à partir de cellules T régulatrices (Treg) pour le traitement de maladies inflammatoires
- 08/25/2016
|
MLB Rumors: Dodgers, Giants, Cardinals Still In Line For Zack Greinke?
- MLB free agent Zack Greinke is reportedly considering signing with the Dodgers or Giants.
- 12/02/2015
|
Print Article
- Visit the post for more.
- 08/14/2014
|
